Fate Therapeutics (FATE) Enterprise Value (2012 - 2026)

Fate Therapeutics has reported Enterprise Value for 15 years, with the latest figure at -$310.1 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 28.96% year-over-year to -$310.1 million; the trailing twelve-month figure through Mar 2026 stood at -$310.1 million (down 28.96% YoY), and the FY2025 full-year result was -$203.7 million, up 27.02% from the prior year.
• Enterprise Value for Q1 2026 stood at -$310.1 million, down from -$203.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$203.7 million in Q4 2025, with the low at -$573.8 million in Q1 2022.
• Historically, Enterprise Value has averaged -$352.5 million across 5 years, with a median of -$315.2 million in 2023.
• Annual changes were most pronounced in 2025 — Enterprise Value surged 37.31% — and 2026, when it retreated 28.96%.
• Fate Therapeutics' Enterprise Value stood at -$436.2 million in 2022, then increased by 27.75% to -$315.2 million in 2023, then rose by 11.46% to -$279.1 million in 2024, then increased by 27.02% to -$203.7 million in 2025, then sank by 52.24% to -$310.1 million in 2026.
• The last three Enterprise Value figures came in at -$310.1 million (Q1 2026), -$203.7 million (Q4 2025), and -$215.4 million (Q3 2025), per Business Quant data.